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Abstract 
I identify two cohorts of cancer patients with known and unknown primary tumours. Cancer 
of unknown primary (CUP) is defined by the presence of pathologically identified metastatic 
disease without clinical or radiological evidence of a primary tumour. Using the Ontario 
Cancer Registry, Same Day Surgery/Discharge Abstract Database and Ontario Health 
Insurance Plan, a novel linkage strategy was developed to cross-validate diagnoses. I found 
CUP patients represent a significant portion of all metastatic cancers. CUP patients with 
histological confirmed disease, squamous cell histology, or metastases localized to nodal 
regions had significantly better survival than other CUP patients. Knowledge of the primary 
site was associated with significantly improved overall survival. Known primary patients 
were more likely to receive treatment than CUP patients. Treatment was associated with 
prolonged survival in CUP patients. Adoption of gene profiling, emphasis on targeted 
therapeutics, and robust clinical guidelines are likely to improve CUP patient outcomes. 
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Chapter 1 : Introduction 
1  
1.1 Background 
Cancer of unknown primary (CUP) patients present with metastatic tumours in 
which a primary tumour cannot be found. These patients are a heterogeneous collection 
of malignancies, bound by an occult primary tumour (1). Treatment of metastatic cancers 
are often linked to the originating neoplasm, as they are of the same biological lineage 
(2). Therefore, physicians will work to identify the primary tumour and categorize its cell 
type in order to direct future treatment. The diagnostic workup to achieve these goals can 
vary by region, however, a detailed medical history of the patient, a complete physical 
examination, a full blood count and biochemical analysis, urinalysis and stool occult 
blood tests, a histopathological review of the tumour biopsy with immunohistochemistry 
(IHC) and computed tomography (CT) scan of the abdomen, thorax and pelvis are 
routinely recommended (3, 4). In some cases mammography, magnetic resonance 
imaging (MRI) and positron emission tomography (PET) may also be employed (5). If, 
however, after extensive clinical and diagnostic work-up a primary tumour site cannot be 
found, the patient is diagnosed as a cancer of unknown primary (CUP) and treated with 
CUP based protocols.  
While the biological mechanisms surrounding CUP are not well understood three 
common clinical explanations are documented in the literature (1). First, the primary 
tumour remains intact but is too small to be detected by conventional diagnostic 
procedures. Second, the primary tumour may have been destroyed by the immune 
system. Third, in rare cases an unrelated surgical procedure may remove the primary 
tumour, for instance via mastectomy. In addition to a latent primary tumour, CUP 
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patients are often typified by these distinct characteristics: multiple metastatic sites, 
atypical metastatic sites and early aggressive metastases (6). Given CUP is a 
heterogeneous malignancy thus historically making an exact definition of CUP difficult 
(6, 7). Many researchers define CUP as: ‘‘histologically confirmed metastatic cancer for 
which clinicians are unable to identify a primary tumour after a standard diagnostic 
approach’’ (8). This definition has become widely accepted, but may still be insufficient. 
First, a “standard diagnostic approach’’ may be anything but standard in such a group of 
patients. Second, population studies have observed the proportion of CUP patients 
without histologically examined tumours between 30.3% to 58.4% (8, 9). These points 
highlight the difficulty in studying this population. 
1.2 Epidemiology 
Estimates of cancer cases resulting in a CUP diagnosis range by country and 
cancer registry, however, an estimate of 3-5% of all cancer cases is often stated, while 
wider estimates of 2-10% have also reported (1, 10). CUP does not rank among the five 
most common cancer diagnoses, but due to the poor prognosis of these patients it is a 
leading cause of cancer death (4). Overall median survival is estimated between 6-10 
months (5). Several CUP patient characteristics are commonly observed. These patients 
tend to be older on average when diagnosed (median age between 65-90) than other 
common cancer types and appear to be more common in men than in women (4, 8, 10, 
11). Recently smoking was shown to be a risk factor for CUP, and was strongly 
associated with patients surviving less than 12 months (12).  
During the course of treatment approximately 5% of patients have their primary 
tumour discovered (6). As many as 75% of patients who undergo an autopsy have their 
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primary tumour found (11, 13). These patients have shown the most common primary 
tumours are found in the pancreas, lung, colon or rectum and liver (3).  
1.3 Classification of Cell Type 
A biopsy of the metastatic tumour can provide valuable information directing 
treatment decisions when a primary tumour is absent. Light microscopy, 
immunohistochemistry (IHC) and less frequently, molecular or genetic diagnostics 
provide valuable information as to the lineage of the metastatic tumour (3). Routine light 
microscopy distinguishes CUP tumour biopsies into four broad categories: 
adenocarcinoma, undifferentiated carcinoma, squamous-cell carcinoma, and 
undifferentiated neoplasm (14). IHC can distinguish cellular identity by utilizing 
chemical stains specific for the following tumour types: carcinoma, lymphoma, sarcoma, 
melanoma, non-seminoma and seminoma. 
The majority of CUP patients (50%) have moderately to well differentiated 
metastatic adenocarcinoma (15). The next most frequent cell type is poorly or 
undifferentiated carcinoma (30%). Of the remaining CUP patients, approximately 15% 
are diagnosed with squamous cell carcinoma and the remaining 5% of patients cannot be 
accurately defined and are labeled as undifferentiated neoplasm. This last category can 
then be potentially further classified using other diagnostic tools. 
1.4 Subsets 
CUP can be referred to as a diagnosis of absence, since the distinguishing characteristic is 
the lack of a detectable primary site. Given this fact, CUP appears to be a group of 
unrelated malignancies. However, this issue is not fully agreed upon in the literature. One 
hypothesis maintains that the biology underscoring CUP has a common basis, potentially 
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having genetic and molecular signatures leading to an occult primary with detectable 
early metastases (11). The opposing view states that CUP is a loosely associated group of 
clinically and biologically heterogeneous tumours, in all of which the primary tumour 
cannot be observed (1). There is evidence to support both claims, with the latter being 
more widely accepted by clinicians (6). 
 CUP patients can be classified as either favourable or unfavourable given 
clinicopathological features (5). The majority of CUP patients (>80%) belong to the 
unfavourable subset and present with adenocarcinoma metastatic to the liver or other 
organs, non-papillary malignant ascites (adenocarcinoma) or multiple metastatic sites. 
These patients do not respond well to treatment and median overall survival is between 6-
10 months (4, 5, 16). The favourable subset responds to specified treatment regimens 
with median overall survival from 12-165 months (11). Characteristics of the favourable 
subset include: poorly differentiated carcinoma with midline distribution (extragonadal 
germ-cell syndrome), women with papillary adenocarcinoma of peritoneal cavity, women 
with adenocarcinoma involving only axillary lymph nodes, squamous cell carcinoma 
involving cervical lymph nodes, isolated inguinal adenopathy (squamous carcinoma), 
poorly differentiated neuroendocrine carcinomas, men with blastic bone metastases and 
elevated PSA (adenocarcinoma) and patients with a single, small, potentially resectable 
metastatic tumour (11, 17). 
1.5 Patient Management 
Directed treatment regimens exist for favourable CUP patients (4, 5). These 
metastatic tumours are treated with a known primary analogue in mind. For instance, 
isolated axillary nodal metastases in females are treated similarly to breast cancer with 
nodal dissection and mastectomy or irradiation of the breast and chemotherapy. For the 
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majority of CUP patients in the unfavourable subset, a general treatment course is 
suggested (18). As recommended by clinical guidelines, a wide-spectrum empiric 
chemotherapy utilizing platinum or platinum/taxane is often prescribed (16). A synthesis 
of treatment outcomes in this subset of CUP patients questioned the benefit from well 
established platinum based regimens over placebo/palliative care (16). No clear benefit 
was demonstrated for the use of chemotherapy in the unfavourable subset of CUP 
patients. 
1.6 Overview of Thesis 
In this thesis I examine two patient cohorts in Ontario with metastatic cancer. The 
first group does not have a primary tumour identified (CUP) and the second have a 
known primary tumour site. I identify, describe and compare these cohorts using patient 
characteristics, tumour characteristics, survival and treatment utilization. I use data from 
the Ontario Cancer Registry, Same Day Surgery/Discharge Abstract Database and the 
Ontario Health Insurance Plan, all accessed through the Ontario Cancer Data Linkage 
project “cd-link”. This thesis is organized as follows:  
 Chapter 2: A brief summary the research objectives and hypotheses 
 Chapter 3: Identification and description of an Ontario CUP population 
 Chapter 4: Identification and description of an Ontario metastatic cancer of 
known primary population, and survival comparison to the Ontario CUP 
population 
 Chapter 5: Comparing the treatment utilization between Ontario metastatic cancer 
patients with and without known primary site 
 Chapter 6: A discussion of the conclusions, contribution and impact of this work  
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Chapter 2 : Research Objectives and Hypothesis 
2  
2.1 Overview 
In this thesis, I plan to investigate the presence of CUP patients in Ontario. Population 
studies have been conducted on this group of patients, but are largely limited to the 
European context (8, 10, 19). To date, the largest CUP population described in Canada, 
consisting of 442 patients, was limited to a narrow definition of CUP (20).This 
population excluded several ICD codes which are routinely used to identify CUP 
populations. Considering the number of CUP cases reported in Europe (10, 19, 21) and 
the poor survival outcomes associated with CUP, this is a group that should be further 
investigated to improve current clinical practice. 
The following research objectives (RO) structured the framework and analytical 
decisions of this work: 
RO1: To identify a cohort of patients with CUP using Ontario administrative 
databases 
RO2: To describe survival outcomes in Ontario CUP patients 
RO3: To describe treatment utilization by CUP patients 
RO4: To compare treatment utilization and survival of patients with metastatic 
cancer of known primary to CUP patients 
These research objectives will be used to test the following hypotheses:  
H1: CUP patients represent a significant metastatic cancer subgroup 
H2: Survival will differ upon the localization of CUP metastases  
H3: CUP patient survival will be lower than in patients with a metastatic cancer of 
known primary 
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H4: CUP patients are treated less intensely than patients with a known primary 
tumour 
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Chapter 3 : Identification and survival outcomes of a cohort of 
patients with cancer of unknown 
3  
3.1 Background 
The primary objective for physicians treating patients presenting with a metastatic 
cancer is to identify the tumour’s site of origin. The typical diagnostic work-up includes a 
detailed analysis of medical history, complete physical examination, full blood count and 
biochemical analysis, urinalysis and stool occult blood tests, histopathological review of 
the metastatic tumour biopsy and computed tomography (CT) scan of the chest, abdomen 
and pelvis (4). If the primary tumour remains occult, examining metastatic tumour 
samples with additional immunohistochemical (IHC) staining becomes crucial in 
establishing a potential originating tissue as well as for directing further examination (5). 
Additionally, tests such as mammography, upper and lower gastro-intestinal endoscopy, 
magnetic resonance imaging (MRI) and positron emission tomography (PET) may be 
considered. If the site of the primary tumour remains unidentified after additional 
diagnostic work-up, then the patient is considered to have cancer of unknown primary 
site or origin (CUP). The overall prognosis of CUP patients is poor, with an estimated 
three- to 10-month median survival (4). While CUP accounts for approximately 3% to 
5% of all incident cancers, it ranks among the top five causes of cancer deaths worldwide 
(1, 22). 
 Currently, little is known about the biology of CUP (1). Epidemiological analyses 
of CUP cases have identified clinicopathological features, including sex, sites of the 
metastatic tumour and histopathology, that predict a favourable prognosis (22-24). About 
20% of CUP patients belong to favourable subsets and respond well after receiving site-
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specific therapies (1, 4, 17). However, the majority of CUP patients do not fit into a 
favourable subset and present with metastatic cancer of major organs and multiple 
metastases (11). While median survival in the unfavourable subgroup is under one year, 
prolonged survival in the favourable subgroup can extend beyond 13 years (11, 17). 
 In this study, I identify a cohort of CUP patients in Ontario, Canada, using 
provincial registries and administrative databases. I describe patient characteristics and 
examine overall survival using subgroups defined by histology and metastatic site. 
Population based studies on CUP patients are common in the European context (8, 10, 
25-27), but are less studied in Canada (20, 28). 
3.2 Materials and Methods 
3.2.1 Data Sources 
 I used the Ontario Cancer Data Linkage project “cd-link” to obtain data from 
population-based administrative databases for Canada’s largest province. The cd-link 
project is a data release mechanism in which patient-level data relevant to cancer research 
are linked at the Institute for Clinical Evaluative Sciences using encrypted health card 
numbers, de-identified, and, with the protections of a comprehensive Data Use 
Agreement (DUA), are provided to investigators at academic institutions in Ontario. 
Through the cd-link project, I gained access to the Ontario Cancer Registry (OCR) 
database and the Canadian Institute for Health Information (CIHI) Same-Day Surgery 
and Discharge Abstract Database (SDS/DAD). Ethics approval was obtained prior to 
accessing these databases. 
Maintained by Cancer Care Ontario (CCO), the OCR is an electronic database 
that tracks all incident cases of cancers and associated mortality in Ontario. The OCR 
contains patient information that is compiled from the following sources: hospital 
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pathology reports with a cancer diagnosis, patient records from CCO, electronic death 
records from the Registrar General of Ontario and hospitalization records documenting a 
cancer diagnosis from SDS/DAD (CIHI). Patient data from these sources are linked using 
probabilistic linkage, and each patient is assigned a unique identifier. For each patient, 
the OCR contains patient information, including their regional cancer centre registration 
date, whether an autopsy was completed, histology of biopsy, cause of death, institution 
of diagnosis, number of primary tumours and their first treatment date. The most up-to-
date patient cancer diagnosis is recorded in the OCR database using the International 
Classification of Diseases 9th (ICD-9) before 2002 and ICD 10th (ICD-10) afterwards. 
The data quality of the OCR has been examined previously and was found to be highly 
accurate(29). 
  The SDS/DAD database contains patient-level data for acute, rehabilitation, 
chronic and day-surgery institutions in Ontario. Each observation in this database 
contains information about one hospital stay (DAD) or one same-day surgery stay (SDS). 
This database contains information regarding sex, date of birth, up to 25 diagnoses per 
hospitalization, procedures undertaken, length of stay and several variables indicating 
resource consumption.  
3.2.2 Identification of CUP Population 
I identified patients using the OCR and the SDS/DAD database. I defined CUP 
cases as any Ontario resident who was registered by the OCR during the period from 
January 1, 2000, to December 31, 2005, with one or more of the following diagnosis 
codes: cancer of unknown primary with metastatic sites localized to lymph nodes (ICD-
9:196/ICD-10:C77), the respiratory or digestive systems (ICD-9:197/ICD-10:C78), other 
specified sites (ICD-9:198/ICD-10:C79), or without specification of metastatic site (ICD-
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9:199/ICD-10:C80). I used the SDS/DAD database to verify CUP diagnosis and inclusion 
in the cohort. I included patients where there was evidence in the SDS/DAD database of 
metastatic disease and CUP diagnosis from two months before until two months after the 
initial diagnosis. I excluded patients whose CUP diagnosis was changed to any other site 
later in the course of the disease and those who had a previous known primary cancer 
diagnosis (Figure 3-1). 
I grouped patients by histology types using the International Classification of 
Diseases for Oncology, 3rd Edition (ICD-O-3) histology codes available from the OCR. 
The following ICD-O-3 codes were utilized: adenocarcinoma (8140-8580), squamous 
cell carcinoma (8050-8089), unspecified carcinoma (8010-8049) and undifferentiated 
(8000-8004). Patients with no histologically confirmed disease (i.e., ICD-O-3 9990) were 
grouped in one category. All remaining ICD-O-3 codes were compiled as “other”. I 
obtained survival data from the OCR, spanning the study period with 5 year follow up.  
3.2.3  Statistical Analysis 
 All statistical analyses were performed using SAS software version 9.3 (SAS 
Institute, Cary, NC, U.S.A). The Kaplan-Meier method was used to generate survival 
curves, the date of diagnosis was the start date for survival analysis and the primary 
endpoint of this analysis was overall survival (OS). I used the log-rank test to assess the 
difference between survival curves of metastatic site and histology. I obtained hazard 
ratios (HRs) and 95% confidence intervals using multivariate Cox regression analyses 
adjusted for age and sex. A forward selection approach was used to construct models. 
Time dependant variables were used to test the proportional hazards assumption. In all 
cases the variables returned p>0.05. All statistical tests were two-tailed and were 
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conducted at the 5% significance level. Cell sizes of fewer than five patients were not 
reported, as required by the cd-link Data Usage Agreement.  
3.3 Results 
Patient and tumour characteristics are summarized in Table 3-1. During the study 
period, 52,619 patients were diagnosed with metastatic cancer, and of those, 3,564 (6.8%) 
had a final diagnosis of CUP. Histological samples provided the most common method 
for confirming diagnosis (43.8%). Confirmation of tumour cell type via histology was 
missing for 1,821 (51.1%) of CUP patients. For CUP patients with confirmed histology, 
metastatic tumours localized to the respiratory or digestive systems were most common 
(42.8%). Over half of all tumours were adenocarcinomas (n=939). There were significant 
variations in histology by tumour location. For example, adenocarcimona was the most 
common histology for respiratory/digestive CUP (67.6%), other specified sites (43.8%) 
and unspecified sites (51.9%), but it only represented 23.4% of nodal CUP. Squamous 
cell carcinoma was the most common histology among nodal CUP (39.4%), but only 
represented 2.1% of respiratory/digestive CUP, 10.3% of other specified site CUP, and 
5.4% of unspecified site CUP.   
There was no difference in survival by gender (Table 3-2). Survival was better for 
younger patients, and this trend was consistent across all age groups. Patients lacking 
histology were older, on average, than those with histology (Table 3-1). Patients without 
histology were more likely to have unspecified site CUP and less likely to have nodal 
CUP compared to patients with confirmed histology. The overall survival of patients with 
known histology was significantly higher than survival among those without histology 
(Figure 3-2). 
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 Only patients with confirmed histology were subject to the following analysis. 
This was done in order to remove any patients who were potentially not subject to 
appropriate diagnostic work-up and therefore may not constitute CUP patients. The 
Kaplan-Meier curves of OS are shown in Figure 3-3. The overall trend is similar among 
respiratory/digestive, other specified sites and unspecified CUP. Nodal CUP patients had 
a significantly higher one-year OS probability of 52.4% (log-rank p<0.0001) compared to 
all other subgroups. Patients with other specified site CUP were the next highest 
surviving group, with a one-year OS probability of 16.6%. 
I stratified OS estimates by histology (Figure 3-4). Generally, patients with 
squamous cell carcinoma had higher one- and three-year OS within each metastatic site 
(Table 3-4). Patients with squamous cell carcinoma had a one-year OS probability of 
59.5%, compared to the next highest one-year OS probability in the adenocarcinoma 
group at 11.3%. Nodal CUP with adenocarcinoma, squamous cell carcinoma or 
unspecified carcinoma histology had significantly better survival compared to similar 
histology tumours of other sites. In nodal CUP with undifferentiated histology, only 
unspecified site CUP had significantly worse survival. Nodal CUP had significantly 
better survival among all comparisons for CUP patients without histology.  
3.4 Discussion 
I identified a cohort of CUP patients in Ontario by cross-validating data from the 
OCR and the SDS/DAD database. This work revealed that CUP patients in Ontario 
represent a significant portion of all metastatic cancers, accounting for approximately 
6.8% of the total. I analyzed five-year survival as well as one-year and three-year hazard 
ratios (HR) subgrouped by metastatic site and histology. I found that survival varied by 
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metastatic site and histology. Patients with nodal CUP had better survival than any other 
CUP metastatic site. Patients with metastases localized to either respiratory or digestive 
regions generally had some of the worst survival outcomes, regardless of histology. 
Among patients with squamous cell carcinoma, those with non-respiratory/digestive 
metastases had the highest survival rates.  
The short time window of data collection and the large cohort size constitute the 
strengths of this study and likely translate into consistent diagnosis and treatment during 
the collection period. This CUP cohort is smaller than those of large, European-based 
population studies of CUP with sample sizes ranging from 18,911 to 57,638 (10, 19, 26). 
However, this work encompassed a six-year period, whereas these studies included 21 
(10) to 47 (26) years of observations. As a consequence, this study did not include CUP 
cases from the 1990s, a period that is suggested to have been the peak of CUP incidence 
from European cancer registries (19, 26). Even without those CUP cases, this sample size 
is comparable, given the collection window. 
Our findings are consistent with previous research. Increased survival in nodal 
CUP patients and patients with squamous cell histology has been described elsewhere (5, 
8, 26) as well as decrased survival in respiratory/digestive CUP patients (30). This work 
largely corroborates what is currently known about CUP, but it also shows unique traits 
of this Canadian cohort. In a large Swedish cohort, Hemminki et al. found 24% survival 
after one year (n=7,730), whereas I observed a one-year survival of 13.7% (n=349) for 
unspecified site CUP patients (10). This variation may be attributed to population 
differences or, more likely, to alternative diagnostic or therapeutic guidelines that 
occurred over the different time frames. If this observed difference can be accounted for 
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by diagnostic or post-diagnostic treatment, it will be important to try and implement this 
aspect into the Canadian setting. 
This Ontario patient population was similar to a previously described CUP 
population based in Alberta, Canada (28). The Alberta population had a mean age of 68, 
was 50% male and with 50% having well differentiated carcinomas, 31% unspecified 
carcinoma, 6% squamous cell carcinoma and 8 % undifferentiated. These patient 
characteristics are nearly identical to those found in the Ontario population. However in 
the Alberta study characteristics including comobidity scores, performance status and 
number of metastatic sites were available. The use of therapeutic treatment was also 
described, with 55% of CUP patients undergoing no treatment. Evaluating the treatment 
received by the Ontario population is natural extension of this work and will aid in 
understanding how current clinical practice may differ across Canada. Several different 
time frames have been used when calculating HRs for population based CUP cohorts. For 
example, Hemminki et al. used a 1-year window (10); Kaaks et al. and Schaffer et al. 
used a 2-year windows (12, 31); Seve et al. used a 3-year window (28) while others have 
used windows (30, 32, 33).  For this study we choose 1 and 2 year windows, which are 
within ranges considered in past studies. 
Among patients with squamous cell carcinoma, those with respiratory/digestive as 
the site had the worst survival outcomes. Lung cancer was identified as the main cause of 
death for extranodal squamous cell carcinoma CUP patients in Sweden (32). Death from 
digestive cancers was also common. This suggests CUP involving respiratory and 
digestive sites are directly linked with patient outcome. Patients with non-
respiratory/digestive squamous cell carcinoma may have their metastatic sites located 
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such that treatment by radiation or surgery is possible. This is especially true for tumours 
located in the head and neck or inguinal area (1). These favourable subgroups often 
present in such a way that a potential originating malignancy is suggested, directing 
therapeutic treatment (34). 
Historically, therapeutic guidelines for CUP patients have recommended the use 
of platinum-based chemotherapy (5, 18, 35). Although targeted treatments may be 
available for some subgroups of patients, platinum-based chemotherapy is often 
recommended to accompany such treatment (11). For the majority of CUP patients, a 
platinum-based doublet regimen is often prescribed (3). A recent systematic review of the 
unfavourable subset of CUP has raised questions about current clinical practice (16). 
Phase II trials completed in the past 15 years have yielded inconclusive results regarding 
chemotherapy over best supportive care, and have not clarified the benefit of treatment 
regimens with platinum-based chemotherapy over non-platinum-based chemotherapy 
with single versus doublet or triplet chemotherapy regimens (16). Future analyses 
describing treatment received by this study cohort is warranted to describe the Canadian 
clinical practice.  
Fifty-one percent of this sample (1,821/3,564) did not have a confirmed histology. 
Given that this group had poor outcomes, with a minority of patients surviving beyond a 
few months (Figure 2), there may be clinical and administrative factors leading to an 
absence of histology. For instance, these patients may not have survived long enough for 
pathology analyses to be conducted. Many of these patients (98%) had operation as their 
method of confirmation. It is possible that for this subgroup, surgery revealed a poor 
prognosis such that histological tests were not ordered. It is also possible that, for some 
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members of this group, CUP diagnosis was used by the registry as a temporary diagnosis 
but was never updated, so that the final record shows unconfirmed histology. Two recent 
population registry studies reported CUP with no histological evidence to comprise 
30.3% and 58.4% of CUP cases (8, 9). While this does not prove the accuracy of the CUP 
diagnosis, it does show these patients represent a significant and clinically visible subset 
of the CUP population. 
The lack of certain information known to be relevant for the CUP population 
represents a limitation of this study. The number of metastatic sites is known to be 
associated with greater disease burden (18). Indeed, one characteristic of the favourable 
subset of CUP patients is a single metastatic site. Additionally, several prognostic scores 
have been proposed with potential factors associated with CUP patient survival. 
However, the OCR does not capture the number of metastatic sites or prognostic markers, 
such as lactate dehydrogenase (LDH) level, albumin level and performance status (16, 
36). Application and validation of a prognostic model in this large CUP patient cohort 
could have important consequences in current clinical practice. Capturing the above data 
elements in administrative databases would significantly enhance research in this area. 
Treatment intensity in this cohort could prove to be valuable in establishing costs for 
treating patients with CUP and the relationship between survival and therapeutic 
procedures. This link has yet to be clearly demonstrated for CUP populations (16). 
 This study shows that CUP patients in Canada constitute a relatively large group 
of the metastatic cancer population and that this population is mainly composed of 
patients in the unfavourable CUP subgroup. Important differences in patient survival 
between this cohort and those identified in previous studies suggest a need for further 
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study. Future research efforts should continue to explore new diagnostic tools for this 
population, especially those with unfavourable characteristics. 
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Table 3-1. Characteristics of patients with cancer of unknown primary by age, gender, site of secondary 
malignancy, histology and method of diagnostic confirmation (n=1743) 
Patient characteristic n (%) 
Age 69 
Male 49.7% 
Site   
     Secondary and unspecified malignant neoplasm of lymph nodes (196/C77) 191 (11.0) 
     Secondary malignant neoplasm of respiratory and digestive systems (197/C78) 746 (42.8) 
     Secondary malignant neoplasm of other specified sites (198/C79) 457 (26.2) 
     Malignant neoplasm without specification of site (199/C80) 349 (20.0) 
Histology   
     Adenocarcinoma  939 (53.9) 
     Squamous cell carcinoma 173 (9.9) 
     Unspecified carcinoma  475 (27.3) 
     Undifferentiated  139 (8.0) 
     Other* 17 (1.0) 
Diagnostic conformation method  
     Histology 1075 (61.7) 
     Cytology 341 (19.6) 
     Operation 194 (11.1) 
     X-Ray 117 (6.7) 
     Unknown 10 (0.6) 
     Judgement or autopsy 6 (0.4) 
*Other includes sarcoma, lymphoma, other hematologic, melanoma and other specified carcinoma 
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Table 3-2. One-year hazard ratio (HR) by gender and age group. 
  n HR P-value 
Gender    
 Male 867 1.06 0.2850 
 Female 876 1.00 ref 
Age at diagnosis    
 <39 31 0.50 0.0010 
 40-49 109 0.55 <.0001 
 50-59 235 0.66 <.0001 
 60-69 399 0.78 0.0007 
 70-79 575 0.86 0.0270 
 >80 394 1.00 ref 
ref = Reference group used for hazard ratio calculation 
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Table 3-3. Cross-tabulation of patients secondary malignancy site by histology (n=1726) 
 
Nodal CUP  
(196/C77) 
Respiratory/digestive CUP 
(197/C78) 
Other specified sites CUP 
(198/C79) 
Unspecified site CUP  
(199/C80) 
Adenocarcinoma  54 504 200 181 
Squamous cell carcinoma 91 16 47 19  
Unspecified carcinoma  41 173 154 107 
Undifferentiated  <5 ǂ 47 51 38 
Total 186-191ǂ 746 457 349 
ǂ  Cell sizes <5 cannot be reported following cd-link guidelines 
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Table 3-4. One-year (1 y) three-year (3 y) survival (%) and the 1 year hazard ratio (HR) stratified by patients secondary malignancy site and histology (n=1726) 
  Nodal CUP  Respiratory/digestive CUP  Other specified sites CUP  Unspecified site CUP 
(196/C77) (197/C78) (198/C79) (199/C80) 
 1 y 3 y HR P-value  1 y 3 y HR P-value  1 y 3 y HR P-value  1 y 3 y HR P-value 
Adenocarcinoma  35.7 13 0.50 0.0002  7.9 3 1.20 0.0486  11.5 4 0.90 0.3383  13.7 5 1.00 n/a 
Squamous cell carcinoma 77.7 59 0.40 0.0201  0 0 3.88 0.0025  51 26.5 1.03 0.9474  52.6 31.6 1.00 n/a 
Unspecified carcinoma  33.3 31 0.40 <.0001  5.2 ǂNR  0.94 0.619  13.5 5.1 0.59 <.0001  3.7 ǂNR  1.00 n/a 
Undifferentiated  ǂNR   4.3 0 0.86 0.5155  17.7 5.9 0.50 0.0027  0 0 1.00 n/a 
Total 56.1 40    6.8 2.4    17.9 8    11.1 4.6   
*Other includes sarcoma, lymphoma, other hematologic, melanoma and other specified carcinoma 
ǂNR = Not reported due to cd-link guidelines  
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Figure 3-1. Cohort identification flowchart 
 
  
Discharge abstract database and 
Same Day Surgery (DAD/SDS) 
database –Hospitalization records 
n = 314,772
2,083,661 records
Cases file – Incident cancer cases 
diagnosed between January 1, 2000 
to December 31, 2005 in Ontario, 
Canada
n = 319,123
Ontario Cancer Registry (OCR) 
database –Most up-to date 
patient  cancer diagnosis
n = 319,123
351,446 records
DAD/SDS hospitalization records for all incident cases of 
cancer within study period
n = 312,714
1,993,676 records
OCR records for all patients diagnosed with cancer within 
study period
n= 319,123
351,446 records
Limiting hospitalization records to those containing a 
CUP diagnosis code (ICD-9 or ICD-10), and a flag for 
metastatic cancer
n = 287,526
792,560 records
Any OCR patient record with a CUP diagnosis code (ICD-9 or 
ICD-10)
n=8,462
OCR and SDS/DAD patient records were merged if the hospitalization record cancer 
diagnosis code matched that in the OCR patient record, hospitalizations were compared 
chronologically
n = 3,564
Final Cohort: Any patients with missing histology were removed from analysis resulting in 
a database with single entries per patient with the most up-to-date cancer diagnosis, 
specific for metastatic cancer and the earliest hospitalization/surgery date specific to that 
CUP code
n = 1,743
1. 1.
2.
5.
3.
4.
Figure 3-1. Cohort identification flowchart
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Figure 3-2. Kaplan-Meier survival curves for CUP patients with a valid histology or 
missing histology. CUP, cancer of unknown primary. 
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Figure 3-2. Kaplan–Meier survival curves for CUP patients with a valid 
histology  r missing hist logy. CUP, cancer of unknown primary.
Log-Rank: p<0.0001 
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Figure 3-3. Kaplan-Meier survival curves for patients with CUP coded as 196, 197, 198 
or 199. CUP, cancer of unknown primary. 
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Figure 3-3. Kaplan–Meier survival curves for patients with CUP coded as 
196, 197, 198 or 199. CUP, cancer of unknown primary.
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Log-Rank: p<0.0001 
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Figure 3-4. Kaplan-Meier survival curves of 
CUP patients with (a) adenocarcinoma (b) 
squamous cell carcinoma (c) unspecified 
carcinoma or (d) undifferentiated histology. 
CUP, cancer of unknown primary. 
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Chapter 4 : Comparison of survival outcomes for metastatic 
tumour of known primary versus cancer of unknown primary 
4  
4.1 Background 
When metastatic tumours are present without an identifiable originating tumour, 
patients are diagnosed with a cancer of unknown primary (CUP). Ideally, patients 
undergo standard diagnostic workup before such a diagnosis can be made (18). Most 
importantly, the cancer should be histologically confirmed to be regarded as a CUP (8). 
One identifying characteristic in a majority of these patients is a poor prognosis and 
median survival is often estimated at less than 12 months (5, 10, 16). Worldwide 
estimates of CUP incidence vary by nation, but is generally thought to account for 3-5% 
of all incident cancers (4, 35).  
 No common underlying biological factor connects CUP patients (4). Therefore it 
is best described as a heterogeneous patient group categorized by an occult primary 
tumour. Given this loose association, methods to identify the primary tumour have been 
at the core of this patient population. Recently, the use of genomic assays to predict a 
primary tumour site has been at the forefront of CUP research. One of the largest clinical 
trials to date (n=252) used the predictive findings to administer assay-directed therapy 
(37).  Overall median survival was 12.5 months, with some tumour types seeing a 29.6 
month overall survival. While it is well documented CUP patients have poor survival 
outcomes, there is little data comparing CUP patients to metastatic cancer patients with a 
known primary site.  
Recently I have identified a CUP population in Ontario, Canada (see Chapter 3). 
Metastatic tumour site was a significant predictor of survival outcomes: CUP patients in 
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which metastases were isolated to nodal regions had a 1-year survival of 56.1%, whereas 
patients with respiratory/digestive metastases had a 1-year survival of 6.8%. CUP 
patients with isolated nodal region metastases often fall into a subgroup deemed the 
favourable CUP subgroup, due to extended survival and increased treatment response 
(11, 18). These patients may have superior survival due to their tumour site suggesting a 
primary tumour, resulting in directed treatment including surgery or radiation. To 
investigate the survival differences between CUP and known primary metastatic cancer 
patients I sought to identify all metastatic cancer patients in Ontario, Canada. Using 
administrative databases I describe this cohort of patients and compare patient 
characteristics, tumour characteristics, overall and subgroup survival to an Ontario CUP 
population previously described (Chapter 3). 
4.2 Methods and Materials 
4.2.1 Data Sources 
The Ontario Cancer Registry (OCR) and the Canadian Institute for Health 
Information (CIHI) Same-Day Surgery and Discharge Abstract Database (SDS/DAD) 
were used in this study. The OCR, an administrative database held by Cancer Care 
Ontario (CCO), combines patient information from existing CCO information, hospital 
pathology reports, Registrar General of Ontario and hospitalization records with a cancer 
diagnosis. The SDS/DAD database documents any Ontario hospital stay (DAD) or 
surgical procedure (SDS) performed in Ontario.  
Access to these databases was granted through a Data Use Agreement (DUA) 
with the Ontario Cancer Data Linkage project (cd-link). This project allows academic 
investigators access to de-identified patient level information. The information is 
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processed at the Institute for Clinical Evaluative Sciences using encrypted health card 
numbers. Ethics approval was obtained prior to accessing these databases. 
4.2.2 Ontario Cancer of Unknown Primary and Ontario Metastatic 
Tumour of Known Primary Population 
Two distinct populations are described in this research:  
1. An Ontario CUP population (Chapter 3)  
2. A novel Ontario metastatic cancer of known primary site cohort.  
Using the OCR, SDS/DAD and a cases database provided through cd-link a novel 
linkage strategy was employed to identify patients with a metastatic tumour of known 
primary tumour site from January 1, 2000, to December 31, 2005 (Figure 4-1). The cases 
database contained all individuals who were diagnosed with cancer within the study 
period. The SDS/DAD database was first merged with a cases database (Step 1, Figure 4-
1). Using the SDS/DAD-cases database (Step 3, Figure 4-1), any patient with a 
hospitalization record with an ICD-10 code matching a cancer diagnosis was identified. 
The OCR database provided information about the primary tumour site, but did not 
distinguish if the malignancy was metastatic. The OCR database was also merged to the 
cases database (Step 2, Figure 4-1). Using the OCR-cases database (Step 4, Figure 4-1), 
all patients with an ICD-10 code indicating an incident cancer diagnosis during the study 
period were identified. Patient identification numbers that matched between these cohorts 
were used to cross validate their cancer diagnosis (Step 5, Figure 4-1). Only patients with 
matching ICD-10 codes were retained. Finally, using a metastatic cancer flag held within 
the SDS/DAD database, any non-metastatic cancer patients were removed from the 
cohort (Step 6, Figure 4-1). Patients were also removed if no histology was present or if 
their diagnosis changed within 60 days of their initial workup. Histological codes were 
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grouped using the International Classification of Diseases for Oncology, 3rd Edition 
(ICD-O-3) from the OCR.  
4.2.3 Statistical Analysis 
All statistical analyses were performed using SAS software version 9.3 (SAS 
Institute, Cary, NC, U.S.A). The Kaplan-Meier method was used to generate survival 
curves, the date of diagnosis was the start date for survival analysis and the primary 
endpoint of this analysis was overall survival (OS). I used the log-rank test to assess the 
difference between survival curves of metastatic site and histology. I obtained hazard 
ratios (HRs) and 95% confidence intervals using multivariate Cox regression analyses 
adjusted for age and sex. A forward selection approach was used to construct models. 
Time dependant variables were used to test the proportional hazards assumption. In all 
cases the variables returned p>0.05. All statistical tests were two-tailed and were 
conducted at the 5% significance level. Cell sizes of fewer than five patients were not 
reported, as required by the cd-link Data Usage Agreement. 
4.3 Results 
I identified 47,090 patients who were metastatic at the time of diagnosis from 
January 2000 to December 2005 with confirmed histology and whose diagnosis remained 
constant during this period. Of these patients 45,347 (96.3%) had an identifiable primary 
site. The remaining 1,743 patients (3.7%) were diagnosed with cancer of unknown 
primary (CUP; Table 4-1). Among the main metastatic sites, CUP ranks as the sixth 
largest group behind gastrointestinal (n=16,308), respiratory (n=12,166), breast 
(n=8,453), gynecological (n=2,637) and urological (n=2,230).  
These patients also differed significantly in their tumour specific characteristics. I 
found the distribution of histological cell types to differ significantly (p<0.0001). CUP 
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patients had a smaller proportion of adenocarcinoma (53.9%) and larger proportion of 
other histologies (36.2%) than known primary metastatic cancers (71.6%, 20.8% 
respectively). CUP patients also differed significantly in their distribution of diagnostic 
confirmation method (p<0.0001). These patients had fewer tumours confirmed via 
histology (61.7%) than known primary patients (87.4%) and many more tumours 
confirmed via operation (11.1% vs. 1.6%). CUP patients were the oldest group at 69.4 
years at diagnosis. Known primary patient average diagnosis age ranged from 45.1 years 
for endocrine tumours to 67.7 years for brain tumours (Table 4-2). 
Overall median survival of CUP patients was poor at 1.9 months compared to 
11.9 months for all known primary cancer patients (Table 4-3). Of known primary sites, 
metastatic liver cancers had the lowest median survival (2.9 months) and breast cancer 
had the highest median survival (>60 months). I computed 2-year HR’s, overall survival 
and survival by histology subgroup using  CUP as the baseline hazard for each 
comparison. All known primary sites combined had a 2-year HR of 0.49 (p<0.0001). 
Nearly all main primary sites had significantly lower hazard than CUP with all 
histology’s considered. This trend was also seen in the adenocarcinoma only comparison, 
however the HR’s tended to be even smaller. When I compared squamous cell carcinoma 
only, all known primary tumours combined had a 2-year HR of 2.04 (p<0.0001) and no 
main primary site had a significantly lower HR. Known primary tumours with an other 
histology tended to be significantly lower than CUP patients with an other histology. 
Survival is shown over a 5-year period for CUP patients and all known primary tumour 
patients (Figure 4-2) and general primary tumour sites (Figure 4-3). 
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4.4 Discussion 
I identified 47,090 metastatic cancer patients in Ontario, Canada. This patient 
population contained a CUP cohort I had previously described (Chapter 3) and the first 
description of all metastatic cancer patients of known primary in Ontario. I observed CUP 
as the sixth largest group of metastatic cancers between January 2000 and December 
2005 in Ontario. I found that knowledge of the primary tumour site was associated with 
longer median survival, 11.9 months compared to 1.9 months when the primary site was 
unknown. I also described a novel linkage strategy independently surveying the OCR and 
the SDS/DAD. 
I observed a decline in cases of metastatic cancer of known primary from a high 
of 8,960 patients in 2000 to a low of 6,345 patients in 2005. The American National 
Center for Health Statistics reported a drop in the incidence of all cancers between 1999-
2005 (38). These data coupled with advances in cancer diagnostics and aggressive 
screening programs could explain this reduction in the number of patients who are 
metastatic at the time of diagnosis. 
 The increased survival observed in patients with metastatic cancer of known 
primary site versus CUP may be attributable to several factors. First, treatment may be 
more common in patients with a known primary site. Second, knowledge of the primary 
site may significantly alter clinical decision making. Third, CUP patients also tend to be 
older than patients with a known primary. The advanced age of CUP patients may be 
correlated to comorbidities, decreasing the likelihood of therapeutic intervention. Finally, 
a large percentage of the known primary metastatic tumours are breast cancer (n=8,453). 
This patient subgroup had the best survival outcome (median survival >60 months). This 
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is likely due to frequent screening and treatment found within this patient population 
(39). 
 Not all CUP patients had worse survival than those with a known primary site. In 
particular, CUP squamous cell carcinoma patients had a lower 2-year HR than all 
squamous cell carcinoma patients with a known primary tumour (HR=2.04, p<0.0001). 
Two factors drove this result. First, of the 3,452 patients with a known primary squamous 
cell carcinoma, 50.2% (n=1,771) had non-small cell lung cancer. This subgroup has been 
established to have poor outcomes with a five year survival of 11% (40). Second, I found 
metastatic cancer subgroups with a median survival above 20 months to be uncommon. 
However, I previously reported a median survival of 20.4 months in Ontario CUP 
squamous cell carcinoma patients (Chapter 3). 
 While I am confident in the survival differences between these two patient 
populations, these results cannot be directly extrapolated to CUP patients in which a 
primary tumour is identified. This work provides no direct evidence that identification of 
a primary tumour is synonymous with increased survival. However, when these results 
are taken together with increasing evidence found in genomic assays, this conclusion 
becomes plausible. As previously mentioned, the use of genomic assays in CUP patients 
found a median overall survival of 12.5 months (n=252), similar to the all known primary 
tumour overall survival of 11.9 months (n=45,347) (37). These results aid the conclusion 
that the identification, or alternatively, treatment based on predictive primary tumours 
provides survival benefit.  
 Overall, CUP patients have worse survival than patients with metastatic cancers 
of known primary site. Determining the value of identifying the putative primary tumour 
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site will be an important topic of research for CUP patients. Likewise, understanding 
fundamental differences between CUP patients and metastatic cancer of known primary 
patients may explain the survival differences I have observed. Investigating the role of 
treatment and treatment intensity may provide better insights into the key difference 
between these patient groups. 
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Table 4-1. Characteristics for patients with metastatic tumours of known primary (n=45,347) and CUP patients (n=1,743)  
 All Known Primary  CUP  
 n %  n %  p-value 
Total n 45,347 100 1743 100  
      
Age (average) 63.7 69.4 <0.0001** 
   <39 2,045 4.5 31 1.78 <0.0001** 
   40-49 5,109 11.3 109 6.3  
   50-59 9,165 20.2 235 13.5  
   60-69 11,814 26.1 399 22.9  
   70-79 11,998 26.5 575 33.0  
   >80 5,216 11.5 394 22.6  
      
Gender      
   Male 19,946 44.0 867 49.7 <0.0001** 
   Female 25,401 56.0 876 50.3  
      
Year of diagnosis      
   2000 8,960 19.8 341 19.6 0.230** 
   2001 7,789 17.2 279 16.0  
   2002 7,432 16.4 291 16.7  
   2003 7,063 15.6 304 17.4  
   2004 7,758 17.1 304 17.4  
   2005 6,345 14.0 224 12.9  
      
Histology      
   Adenocarcinoma 32,450 71.6 939 53.9 <0.0001** 
   Squamous cell carcinoma 3,452 7.6 173 9.9  
   Other1 9,445 20.8 631 36.2  
      
Diagnostic method      
   Autopsy 46 0.1 <5ǂ <0.0001** 
   Cytology 3,900 8.6 341 19.6  
   Histology 39,653 87.4 1,075 61.7  
   Operation 725 1.6 194 11.1  
   Other2 1,023 2.3 132 7.6  
      
Main Primary Site      
   Gastrointestinal 16,308 34.6 -  
   Respiratory 12,166 25.8 -  
   Breast 8,453 18.0 -  
   Gynecological 2,637 5.6 -  
   Urological 2,230 4.7 -  
   Head and neck 1,049 2.2 -  
   Endocrine 722 1.5 -  
   Sarcoma 697 1.5 -  
   Lymphoma 574 1.2 -  
   Melanoma of the skin 416 0.9 -  
   Leukemia 30 0.1 -  
   Brain 14 0.0 -  
   All other3 51 0.1 -  
1Includes: Unspecified carcinoma, undifferentiated, sarcoma, lymphoma, other hematologic, melanoma and other specified carcinoma 
2Includes: Unknown and pathology report outside of country 
3Includes: Bone joints, soft tissue heart, eye adnexa and ill defined sites. 
ǂCells containing less than 5 patients not reported in accordance with the cd-link DUA 
*t-test 
**Fisher’s exact test 
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Table 4-2.Patient and tumour characteristics for metastatic cancer patients with known primary and CUP stratified by 
cell type 
 n (%) 
Mean 
Age 
Male 
(%) 
 
Histology 
Primary Tumour Site    
Adenocarcinoma 
(%) 
 
Squamous Cell 
(%) 
 Other (%) 
        
Gastrointestinal 16,308 66.7 56.5  15,219 93.3 307 1.9 782 4.8 
   Colorectal 10,506 67.3 54.3  10,192 97.0 55 0.5 259 2.5 
   Stomach 2,133 65.8 64.7  2,025 94.9 14 0.7 94 4.4 
   Pancreas 1,853 65.5 53.9  1,562 84.3 <5ǂ 0.1-0.3 286-290 15.4-15.7 
   Esophagus 683 64.3 78.9  413 60.5 223 32.7 47 6.9 
   Gall bladder 272 68.6 30.9  225 82.7 8 2.9 39 14.3 
   Small intestine 262 62.8 57.6  250 95.4 <5ǂ 0.4-1.9 11-15 4.2-5.7 
   Liver1 193 62.9 71.5  182 94.3 0 0.0 11 5.7 
   Other gastrointestinal2 406 66.0 51.2  370 91.1 <5ǂ 0.2-1.2 31-35 7.6-8.6 
Respiratory 12,166 65.8 56.2  4,694 38.6 1,77
1 
14.6 5,701 46.9 
   Non-small lung 9,314 65.6 56.6  4,522 48.6 1,73
4 
18.6 3,058 32.8 
   Small lung 2,816 66.5 55.0  164 5.8 25 0.9 2,627 93.3 
   Other respiratory3 36 60.6 63.9  8 22.2 12 33.3 16 44.4 
Breast 8,453 57.8 0.8  8,291 98.1 15 0.2 147 1.7 
Gynecological 2,637 63.4 0.0  2,206 83.7 214 8.1 217 8.2 
               Ovarian 1,991 64.0 0.0 1,806 90.7 13 0.7 172 8.6 
   Uterine 379 64.9 0.0  352 92.9 6 1.6 21 5.5 
   Cervical 171 52.3 0.0  43 25.1 114 66.7 14 8.2 
   Other gynecological4 96 65.5 0.0  5 5.2 81 84.4 10 10.4 
Urological 2,230 66.4 80.9  1,450 65.0 41 1.8 739 33.1 
   Prostate 845 73.3 99.9  737 87.2 <5ǂ 0.1-0.6 107-111 12.7-13.1 
   Kidney renal pelvis 835 63.2 66.0  683 81.8 9 1.1 143 17.1 
   Bladder 397 69.3 66.3  27 6.8 29 7.3 341 85.9 
   Other urological5 153 38.6 94.8  <5ǂ 0.7-3.3 <5ǂ 0.7-3.3 148 96.7 
Head and neck 1,049 58.9 75.6  71 6.8 910 86.7 68 6.5 
   Pharynx 393 55.9 77.4  <5ǂ 0.3-1.3 341 86.8 45-49 11.5-12.5 
   Larynx 116 62.6 82.8  <5ǂ 0.9-4.3 111-
115 
95.7-99.1 0 0.0 
   Other head and neck6 540 60.2 72.8  64 11.9 456 84.4 20 3.7 
Endocrine 722 45.1 36.8  507 70.2 166 23.0 49 6.8 
   Thyroid 680 44.4 35.7  480 70.6 163 24.0 37 5.4 
   Other endocrine7 42 55.0 54.8  27 2.4-11.9 <5ǂ 19.0-28.6 10-14 23.8-33.3 
Sarcoma 697 51.3 47.1  0 0.0 0 0.0 697 100.0 
Lymphoma 574 65.1 57.0  0 0.0 0 0.0 574 100.0 
    Non-Hodgkin’s lymphoma 527 66.7 55.4  0 0.0 0 0.0 527 100.0 
   Other lymphoma8 47 46.9 74.5  0 0.0 0 0.0 47 100.0 
Melanoma of the skin 416 57.2 63.0  0 0.0 0 0.0 416 100.0 
Leukemia 30 65.0 63.3  0 0.0 0 0.0 30 100.0 
Brain 14 67.7 21.4  <5ǂ 7.1-35.7 0 0.0 9-13 64.3-92.9 
All other9 51 63.2 56.9  10 19.6 28 54.9 13 25.5 
All Known Primary 45,347 63.7 44  32,450 71.6 3,45
2 
7.6 9445 20.8 
CUP  1,743 69.4 49.7  939 53.9 173 9.9 631 36.2 
1Includes hepatocellular and non-hepatocellular; 2Includes biliary tract, bile duct, mesothelioma, retroperitoneum , peritoneum other and ill-defined digestive 
organs; 3Includes nasal cavity, middle ear, accessory sinuses, trachea, ill-defined respiratory and mesothelioma; 4Includes vulva, vaginal and placenta; 5Includes 
testicular germcell, testicular non-germcell, ureter and other and unspecified sites of male genitals; 6Includes salivary gland and ill-defined head and neck; 
7Includes thymus, adrenal gland and other endocrine glands; 8Includes lymphoid and other haematopoietic; 9Includes eye adnexa, independent (primary) multiple 
sites, soft tissue heart, bone and articular cartilage of limbs and other sites meninges, spinal cord, cranial nerves and other parts of the central nervous system 
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Table 4-3. Median survival and two year hazard ratios (HR) stratified by primary site and 
histology 
 
Median 
survival 
(months) 
 All  
Adenocarcinom
a 
 
Squamous 
cell 
carcinoma 
 Other 
Primary Tumour Site 
  
HR p-value  
H
R 
p-value  
H
R 
p-
value 
 
H
R 
p-value 
Gastrointestinal 11.8  0.4
3 
<.0001  0.2
8 
<.0001  2.5
8 
<.0001  1.0
1 
0.8418 
   Colorectal 20.4  0.2
9 
<.0001  0.1
9 
<.0001  1.5
5 
0.0223  0.8
8 
0.1021 
   Stomach 5.9  0.6
7 
<.0001  0.4
6 
<.0001  2.3
8 
0.0048  0.9
2 
0.4302 
   Pancreas 3.0  1.0
7 
0.0734  0.7
4 
<.0001  <5 ǂ  1.2
8 
0.0007 
   Esophagus 4.6  0.8
7 
0.0032  0.6
1 
<.0001  3.0
0 
<.0001  0.7
5 
0.0711 
   Gall bladder 3.1  1.0
2 
0.8203  0.7
0 
<.0001  3.1
8 
0.0033  1.2
7 
0.1529 
   Small intestine 18.2  0.3
4 
<.0001  0.2
3 
<.0001  <5 ǂ  0.7
6 
0.4223 
   Liverl 2.9  1.1
1 
0.1828  0.7
8 
0.0035  N/A*  1.3
2 
0.3654 
   Other 
gastrointestinal2 
6.7  0.6
1 
<.0001  0.4
2 
<.0001  <5 ǂ  0.8
4 
0.3558 
Respiratory 3.7  0.7
6 
<.0001  0.5
7 
<.0001  2.7
7 
<.0001  0.7
8 
<.0001 
   Non-small lung 3.7  0.8
0 
<.0001  0.5
8 
<.0001  2.8
2 
<.0001  0.8
2 
<.0001 
   Small lung 3.6  0.6
6 
<.0001  0.3
1 
<.0001  1.7
5 
0.0296  0.7
5 
<.0001 
   Other respiratory3 9.2  0.4
6 
<.0001  0.3
5 
0.0108  1.6
6 
0.1486  0.4
5 
0.0068 
Breast N/A  0.1
1 
<.0001  0.0
7 
<.0001  0.6
8 
0.3938  0.5
0 
<.0001 
Gynecological 19.6  0.3
5 
<.0001  0.2
2 
<.0001  1.7
6 
<.0001  0.5
1 
<.0001 
   Ovarian 20.3  0.3
2 
<.0001  0.2
1 
<.0001  1.8
4 
0.0819  0.4
6 
<.0001 
   Uterine 18.3  0.3
4 
<.0001  0.2
1 
<.0001  3.4
4 
0.0035  1.2
8 
0.2618 
   Cervical 11.9  0.5
9 
<.0001  0.2
5 
<.0001  2.3
3 
<.0001  0.6
3 
0.1072 
   Other gynecological4 14.3  0.3
8 
<.0001  0.2
1 
0.0069  1.2
2 
0.2567  0.4
3 
0.0271 
Urological 9.8  0.4
27 
<.0001  0.3
0 
<.0001  2.9
9 
<.0001  0.4
4 
<.0001 
   Prostate 15.3  0.2
91 
<.0001  0.2
0 
<.0001  <5 ǂ  0.3
7 
<.0001 
   Kidney renal pelvis 5.7  0.6
38 
<.0001  0.4
5 
<.0001  4.9
2 
<.0001  0.6
6 
<.0001 
   Bladder 5.4  0.4
67 
<.0001  0.7
8 
0.2209  3.3
5 
<.0001  0.4
7 
<.0001 
   Other urological5 38.4  0.2
27 
<.0001  <5 ǂ  <5 ǂ  0.2
6 
<.0001 
Head and neck 25.1  0.2
7 
<.0001  0.1
8 
<.0001  0.9
8 
0.867
5 
 0.2
4 
<.0001 
   Pharynx 36.5  0.2
7 
<.0001  <5 ǂ  0.95 0.681
1 
 0.2
4 
<.0001 
   Larynx 14.6  0.3
8 
<.0001  <5 ǂ  1.26 0.142
9 
 0.2
3 
<.0001 
   Other head and neck6 24.8  0.2
8 
<.0001  0.1
8 
<.0001  0.9
6 
0.711
4 
 0.9
0 
0.5669 
 Endocrine 20.8  0.4
4 
<.0001  0.2
6 
<.0001  1.6
9 
0.000
6 
 0.9
1 
0.56 
   Thyroid 22.6  0.4
3 
<.0001  0.2
5 
<.0001  1.7
4 
0.000
3 
 0.9
9 
0.9585 
   Other endocrine7 7.9  0.5
9 
0.0035  0.3
5 
<.0001  <5 ǂ  0.3
1 
<.0001 
Sarcoma 9.2  0.4
3 
<.0001  N/A*  N/A*  0.5
0 
<.0001 
Lymphoma 10.0  0.2
8 
<.0001  N/A*  N/A*  0.3
2 
<.0001 
     Non-Hodgkin’s 
lymphoma 
10.0  0.2
7 
<.0001  N/A*  N/A*  0.4
2 
<.0001 
   Other lymphoma8 11.5  0.3
6 
<.0001  N/A*  N/A*  1.0
2 
<.0001 
Melanoma of the skin 22.5  0.2
0 
<.0001  N/A*  N/A*  0.2
3 
<.0001 
Leukemia 5.0  0.4
4 
<.0001  N/A*  N/A*  0.4
9 
0.0007 
Brain 4.6  0.6
8 
0.2052  <5 ǂ  N/A*  1.0
9 
0.7703 
All other9 5.7  0.5
0 
<.0001  0.9
1 
0.7775  1.1
7 
0.582
1 
 0.6
1 
0.1057 
 All Known Primary 11.9  0.4
9 
<.0001  0.2
6 
<.0001  2.0
4 
<.000
1 
 0.6
6 
<.0001 
CUP 1.9  ref  ref  ref  ref 
1Includes hepatocellular and non-hepatocellular; 2Includes biliary tract, bile duct, mesothelioma, retroperitoneum , peritoneum other and ill-defined 
digestive organs; 3Includes nasal cavity, middle ear, accessory sinuses, trachea, ill-defined respiratory and mesothelioma; 4Includes vulva, vaginal and 
placenta; 5Includes testicular germcell, testicular non-germcell, ureter and other and unspecified sites of male genitals; 6Includes salivary gland and ill-
defined head and neck; 7Includes thymus, adrenal gland and other endocrine glands; 8Includes lymphoid and other haematopoietic; 9Includes eye 
adnexa, independent (primary) multiple sites, soft tissue heart, bone and articular cartilage of limbs and other sites meninges, spinal cord, cranial nerves 
and other parts of the central nervous system 
  
  
38 
 
 
Figure 4-1. Cohort identification flowchart. 
 
 
 
 
Discharge abstract database and 
Same Day Surgery (DAD/SDS) 
database –Hospitalization records 
(n = 314,772)
Cases file – Incident cancer cases 
diagnosed between January 1, 2000 
to December 31, 2005 in Ontario, 
Canada
(n = 319,123)
Ontario Cancer Registry (OCR) 
database –Most up-to date 
patient  cancer diagnosis
(n = 319,123)
All incident cases of cancer within study period with at 
least one record in the DAD/SDS database 
(n = 314,772)
All incident cases of cancer within study period with 
cancer a record in the OCR
(n= 319,123)
Any patient with a matching ICD-10 code
(n = 282,556)
Any patient with a matching ICD-10 code
(n=282,194)
All incident cases of cancer within study period who had a matching ICD-10 code from the 
OCR and the SDS/DAD database
(n=235,191)
All incident cases of cancer within study period who had a matching ICD-10 code from the 
OCR and the SDS/DAD database. Records were limited to patients with a metastatic 
cancer flag from the SDS/DAD, confirmed histology, and diagnosis remained constant 
after 60 days of diagnosis
(n=47,090)
1. 2.
3. 4.
5.
6.
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Figure 4-2. Kaplan-Meier 5 year survival curve for cancer of unknown primary (CUP) and all known primary tumour 
patients. 
 
Figure 4-3. Kaplan-Meier 5 year survival curve for cancer of unknown primary (CUP) and all known primary tumour 
patients stratified by general primary site.  
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Chapter 5 : Treatment utilization and intensity for patients 
with metastatic cancer of known and unknown primary site 
5  
5.1 Background 
In a majority of metastatic cancer patients the primary tumour is identified 
through the standard diagnostic workup. This is not the case for an estimated 3-5% of all 
incident cancers termed cancer of unknown primary (CUP) (1). Currently, the widely 
accepted definition of CUP requires the metastatic site tumour to be histologically 
confirmed (9). These patients are often typified with a poor prognosis, estimates of 
survival are often below one year (8, 10, 16). 
 Although clinical guidelines exist for this population, for an estimated 80% of 
patients the recommended treatment is a wide-spectrum empiric chemotherapy (5, 16, 18, 
41). However, a synthesis of clinical trials involving CUP patients questioned the 
therapeutic benefit of chemotherapy (16). The authors found no evidence to support 
chemotherapy over best supportive care, no evidence for platinum based chemotherapy 
over non-platinum based chemotherapy and no evidence to support multi-agent 
chemotherapy regimen over single agent treatment. These results are not entirely 
surprising as CUP is believed to represent a heterogeneous population of tumours rather 
than a single entity (6). The lack of progress in treatment information for the majority of 
CUP patients remains problematic for clinicians. 
 While population studies of CUP are common, the relationship between patient 
outcomes and treatment is scarce. A Canadian CUP population study found that 55% of 
patients did not receive any treatment, with younger age being significantly related to 
receiving treatment (28). In an American CUP population 79.7% of patients did not 
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receive radiation therapy and those that did were associated with longer life (9). Recently 
CUP patients and patients with a known primary tumour were identified from the 
Australian Government Department of Veterans’ Affairs (DVA) (31). In this population 
30% of CUP received treatment with a median survival of 37 days compared to 70% of 
known primary patients with a median survival of 310 days.  
 I attempt to address the limited information in CUP treatment by summarizing 
chemotherapy, radiation and surgeries undergone by Ontario metastatic cancer patients. I 
analyze two previously described cohorts: CUP and cancer of known primary site 
patients from Ontario, Canada (Chapters 3-4). I present whether or not treatment was 
administered, types of treatment, if multiple treatment types were used and 
survival/hazard ratios associated with those subgroups. I aim to identify treatment 
differences upon knowledge of the primary site, and how these patient groups differ in 
their response to various treatments. 
5.2 Methods and Materials 
5.2.1 Data Sources 
Ontario residents diagnosed with cancer are tracked though the Ontario Cancer 
Registry. This database is updated annually by Cancer Care Ontario (CCO) and combines 
patient level data from multiple administrative sources. Tumour histology, date of 
death/cause (if applicable) and International Classification of Diseases 10th revision code 
are available from this resource. 
The Ontario Health Insurance Plan is a provincial health insurance plan 
administered by the Ministry of Health and Long-Term Care for residents of Ontario, 
Canada. OHIP is restricted to Canadian citizens, Permanent Residents or individuals with 
a work permit who solely or primarily reside in Ontario. Physician services are recorded 
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by OHIP on a fee-for-services basis and include consultations and visits, nuclear 
medicine, diagnostic imaging, radiation, treatment course planning, surgical procedures 
and drug administration. Fee codes are outlined in the Schedule of Benefits for Physician 
Services Ontario (SOB). 
All Ontario hospital stays or same-day surgeries are recorded in the Canadian 
Institute for Health Information (CIHI) Same-Day Surgery and Discharge Abstract 
Database (SDS/DAD). This database records patient information and procedure/disease 
information for each hospital stay/surgery. 
The Ontario Cancer Data Linkage project “cd-link” allowed us access to the 
aforementioned databases. Through a Data Use Agreement (DUA) I was given access to 
de-identified patient information processed by the Institute for Clinical Evaluative 
Sciences. Ethics approval was obtained prior to accessing these databases. 
5.2.2 Study Population 
I have previously described two metastatic cancer populations. An Ontario CUP 
population was identified from the OCR (Chapter 3). A second cohort of patients who 
were metastatic at the time of diagnosis was identified by merging the OCR and 
SDS/DAD hospitalization files (Chapter 4).  
5.2.3 Treatment Data 
Both study populations were merged with the OHIP database to obtain treatment 
data . I filtered this merged dataset to identify codes for surgery, chemotherapy or 
therapeutic radiation related to oncology. 
5.2.4 Statistical Analysis 
All statistical analyses were performed using SAS software version 9.3 (SAS 
Institute, Cary, NC, U.S.A). The Kaplan-Meier method was used to generate survival 
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curves, the date of diagnosis was the start date for survival analysis and the primary 
endpoint of this analysis was overall survival (OS). I used the log-rank test to assess the 
difference between survival curves of metastatic site and histology. I obtained hazard 
ratios (HRs) and 95% confidence intervals using multivariate Cox regression analyses 
adjusted for age and sex. A forward selection approach was used to construct models. 
Time dependant variables were used to test the proportional hazards assumption. In all 
cases the variables returned p>0.05. All statistical tests were two-tailed and were 
conducted at the 5% significance level. Cell sizes of fewer than five patients were not 
reported, as required by the cd-link Data Usage Agreement. 
5.3 Results 
Table 5-1 shows characteristics of patients with a metastatic tumour of known 
primary (n=45,347) and CUP with confirmed histology (n=1,743).  Patients with a known 
primary site were more likely to receive any treatment type (n=35,012; 77.2%) than 
patients with an unknown primary site (n= 891; 51.1%). CUP patients were most likely to 
receive a single type of treatment (73.1%), while known primary patients were more 
likely to receive two or three different types of treatment (55.3%). Patients with CUP 
who did or did not receive treatment were significantly older than their known primary 
counterparts (p<0.0001). CUP patients who received treatment were younger on average 
(67.7 years) than CUP patients who did not receive treatment (71.2 years). CUP patients 
who received treatment were more likely to have a squamous cell histology (16.2%) than 
CUP patients who did not receive treatment (3.4%). 
I observed that receiving any treatment was associated with higher median 
survival. Patients with known primary tumours who received any treatment type had a 
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median survival of 19.0 months. Patients with known primary tumours who did not 
receive any treatment had a median survival of 2.2 months. A similar trend was observed 
in CUP patients with treated patients having a median survival of 3.6 months and non-
treated patients having a 1.1 month median survival.  
 I compared two year hazard ratios (HR) for the each treatment type (Table 5-2). 
CUP patients who received no treatment were used as the baseline hazard for each set of 
comparisons. For radiation, chemotherapy and surgeries I observed the following trends. 
First, receiving treatment was associated with better survival for CUP and known primary 
patients. In all cases the HR in the untreated groups were higher than the treated groups. 
Second, HR’s decreased with more intensive treatment. Third, even with comparable 
treatment, CUP patients had worse survival outcomes than patients with a known 
primary. For example, I compared patients who received no surgery, a single surgery or 
two or more surgeries. The resulting two year HR’s were 1.00 (ref), 0.82 (p=0.0077) and 
0.48 (p<0.0001) in CUP patients but 0.51 (p<0.0001), 0.34 (p<0.0001) and 0.25 
(p<0.0001) in the known primary group.  
 I investigated survival outcomes associated with the use of more than one type of 
therapy. CUP patients administered any single treatment saw an increased survival over 
CUP patients receiving no treatment (Figure 5-1; Table 5-2).The two year HR’s for 
surgery only 0.54 (p<0.0001), chemotherapy only 0.42 (p<0.0001), and radiation only 
0.36 (p<0.0001) reflect this increase. The addition of a second therapy was associated 
with further survival benefit. All three therapies in tandem were no worse than any two 
therapies. Two year HR’s followed a similar trend for patients with a known primary site, 
though more pronounced.  
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 I investigated any differences when treatment was administered between these 
two patient populations. Figure 5-3 shows the proportion of patients divided into three 
groups: treatment received within 6 months of diagnosis, treatment received after 6 
months of diagnosis or no treatment received. These were then plotted by patient survival 
groups in 6 month increments. Patients with known primary site who survived longer 
were more likely to receive treatment than those who died earlier. The proportion of 
known primary patients who received no treatment decreases from over 60% of patients 
surviving up to 6 months to only 5% of patients surviving more than 60 months. The 
increase in the proportion of patients who received treatment within 6 months of 
diagnosis largely accounted for this change, starting at 34.2% at 6 month survival and 
growing to 85.6% at over 60 month survival. Among CUP patients, survival did not 
appear to have any relation to first treatment date. The proportion of CUP patients who 
did not receive any treatment remains above 50% for the majority of patient survival 
length. The pre-six month treatment and post-six month treatment groups also maintain a 
consistent proportion over patient survival length. 
5.4 Discussion 
To my knowledge this work represents the first direct comparison of treatment 
utilization in CUP patients and metastatic cancer of known primary patients in the 
general population. Using two previously described patient populations, I have described 
the treatment received by CUP and metastatic cancer of known primary patients in 
Ontario, Canada (Chapter 3 and 4). Only 22.8% of metastatic cancer of known primary 
patients did not receive any of the treatments types studied, whereas 48.9% of CUP 
patients did not receive any treatment. I found that receiving any treatment was 
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associated with survival benefit in both patient populations. I was able to show that early 
treatment was correlated with extended survival in known primary patients but was 
largely independent of survival in CUP patients.  
 Our estimate of the proportion of metastatic cancer patients of known primary not 
receiving treatment is similar to what has been described elsewhere. A study of the 
American National Cancer Database for 8 common solid tumour types found 20.6% 
(n=159,284) of all patients across all types of tumours did not receive any treatment (42). 
The authors attributed most non-treatment to poor functional status, comorbidities and 
patient preference. Given the high proportion of CUP patients who did not receive any 
treatment coupled with their poor prognosis and diminished median survival, these 
characteristics are likely to describe a significant proportion of the CUP patient 
population. The addition of comorbidities in the CUP and known primary patient 
population would likely reveal one additional factor associated with treatment 
differences. 
 Methodologically this work is similar to an Australian comparison between CUP 
patients and known primary tumour patients (31). However, I obtained my cohort from 
the general population whereas the Australian work surveyed the Australian Government 
Department of Veterans’ Affairs (DVA). Despite this difference, several key findings 
were similar. Both studies found CUP patients are less likely to be treated than patients 
with known primary, Schaffer et al. observed 30% CUP treated and 70% of known 
primary treated; the corresponding figures I found were 51.1% and 77.2% respectively. 
Both studies also observed poor survival among the CUP patients compared to those with 
a known primary tumour.  
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 There has been some discussion as to the role of chemotherapy in the treatment of 
patients with CUP. Clinical guidelines recommend the use of platinum based 
combination empiric therapies for the majority of CUP patients (5, 18, 41). CUP patients 
treated with combination chemotherapy have an estimated median survival of 9 to 13 
months (43). Whether or not this is a significant benefit over best supportive care remains 
in question (16). These results show significant reduction in 2-year HR’s in 
chemotherapy treated patients. I observed no additional survival benefit associated with 
multi-agent chemotherapy regimens in CUP patients. This is similar to another study that 
found CUP patients receiving carboplatin and paclitaxel, cisplatin and gemcitabine or 
gemcitabine monotherapy showed no significant difference in the Log rank test 
(p=0.0656) (30).  
The benefit of therapeutic treatment has been described in the CUP population, 
however these results have been limited to a single therapy type (9, 30, 44). I observed 
that patients receiving chemotherapy in addition to radiation, surgery or both experienced 
even further survival benefit. No population data to date has shown the survival benefit 
associated with multiple treatment types for CUP patients. However, the clinical 
significance of this result may be minimal as the addition of surgery or radiation may not 
be tenable in some patients.  
PET scans are becoming increasingly utilized in the diagnostic workup of CUP 
patients (45). PET scans can be used in patients who cannot take iodine or who have 
renal insufficiency (34). In certain CUP patients PET scans are recommended including 
those with squamous cell lymphadenopathy of the neck (45). In these patients a primary 
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tumour is found approximately 50% of the time, and resulting PET image can guide 
therapy. The utilization of this technique may correlate with long surviving CUP patients.  
Although I have found strong associations between treatment and survival, I am 
unable to indicate causation. Whether a patient is treated, especially those without a 
primary tumour site, may be related to patient health. Alternatively, CUP patients who 
receive treatment may be fundamentally different from those who do not. There are some 
potential indications this may be the case in this population. First, the proportion of 
squamous cell carcinoma CUP patients who received any treatment was 16.2%, and those 
without treatment numbered 3.4%. This histology is often associated with the favourable 
subgroup of CUP and I have previously shown median survival to be as high as 20.4 
months in this group (Chapter 3). Second, the proportion of CUP patients who received 
no treatment did not change dramatically with patient survival. This same proportion 
decreased sharply for patients with a known primary site. This gives confidence to 
attribute survival benefit to treatment in known primary patients, but not in the CUP 
population.  
While this work describes the utilization of the most common types of therapy 
associated with CUP, other modalities including immunotherapy and targeted therapy 
exist. I am confident this work describes the treatment undergone by the majority of CUP 
patients. This is largely due to the fact that current clinical guidelines rarely recommend 
treatment outside of chemotherapy, surgery or radiation (5, 18, 41). The most recent 
European Society of Medical Oncology CUP guideline indicates chemotherapy, radiation 
or surgery in 7 of the 8 classifications of favourable CUP patients and for all subtypes of 
unfavourable CUP patients (18). Furthermore, in patients where targeted treatment is 
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recommended, the use of surgery, chemotherapy or radiation is also prescribed. For 
example hormonal therapy is recommended for the following CUP patients: 1. male 
patients showing elevated PSA levels suggesting a prostate primary tumour and 2. female 
patients with isolated axillary nodal metastases often resulting from a breast cancer 
primary tumour (18). Even in the later scenario, surgery and radiation is also 
recommended. 
 I have shown there is a survival benefit associated with all treatment types 
surveyed in this work. The observed increase in survival benefit was not uniform across 
the patient groups. Patients with metastatic tumour of known primary experienced greater 
survival benefit than their CUP peers and were far more likely to receive treatment. The 
direct relationship between treatment and survival remains less clear for CUP patients 
than those with a known primary site. Advancing clinical guidelines for CUP patients 
towards specific and specialized care while also expanding treatment to those who would 
normally go untreated is vital for this population.   
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Table 5-1. Characteristics for patients with metastatic tumours of known primary receiving surgery, chemotherapy or radiation (n=35,012), cancer of unknown 
primary (CUP) patients receiving surgery, chemotherapy or radiation (n=891), patients with metastatic tumours of known primary receiving no surgery, 
chemotherapy or radiation (n=10,335) and CUP patients receiving no surgery, chemotherapy or radiation (n=852) 
 
Patients who received surgery, chemotherapy or 
radiation  
 Patients who did not receive surgery, chemotherapy or 
radiation 
 
 
Metastatic cancer with 
known primary CUP  
 Metastatic cancer with 
known primary 
CUP  
 n % n % p-value  n % n % p-value 
Total n 35,012  891    10,335  852   
Mean Age 62.0  67.7  <0.0001*   69.5  71.2 <0.0001* 
     <39 1,787 5.1 17 1.9   258 2.5 14 1.6  
     40-49 4,626 13.2 76 8.5   483 4.7 33 3.9  
     50-59 7,866 22.5 143 16.1   1,299 12.6 92 10.8  
     60-69 9,348 26.7 213 23.9   2,466 23.9 186 21.8  
     70-79 8,446 24.1 267 30.0   3,552 34.4 308 36.2  
     >80 2,939 8.4 175 19.6   2,277 22.0 219 25.7  
Gender     <0.0001*      0.0270* 
     Female 20,374 58.2 428 48.0   5,027 48.6 448 52.6  
     Male 14,638 41.8 463 52.0   5,308 51.4 404 47.4  
Cell type     <0.0001**      <0.0001** 
     Adenocarcinoma 25,846 73.8 472 53.0   6,604 63.9 467 54.8  
     Squamous cell carcinoma 2,487 7.1 144 16.2   965 9.3 29 3.4  
     Other 6,679 19.1 275 30.9   2,766 26.8 356 41.8  
Median Survival (months) 19.0 3.6   2.2 1.1  
Treatment type            
     None  N/A <0.0001**  10,335 100 852 100  
     Surgery only 6,237 17.8 372 41.8   
N/A 
 
     Chemotherapy only 6,503 18.6 141 15.8    
     Radiation only 2,889 8.3 138 15.5    
     Chemotherapy and radiation 3,533 10.1 44 4.9    
     Surgery and radiation 2,356 6.7 107 12.0    
     Surgery and chemotherapy 7,009 20.0 65 7.3    
     Surgery, radiation and 
chemotherapy 
6,485 18.5 24 2.7    
*t-test 
**Fisher’s exact test 
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Table 5-2. Two year hazard ratios (HR) for patients with metastatic tumours of known primary and CUP, 
stratified by type of treatment received. Models adjusted for age, sex and histology 
 Metastatic with known primary 
(n=35,012) 
 CUP (n=891) 
 n % HR p-value  n % HR p-value 
Radiation treatments          
0 30,084 66.3 0.42 <.0001  1,430 82.0 ref 
1-2 13,138 29.0 0.31 <.0001  274 15.7 0.42 <.0001 
3-4 1,638 3.6 0.29 <.0001  33 1.9 0.40 <.0001 
>5 487 1.1 0.26 <.0001  6 0.3 0.34 0.0084 
Chemotherapy          
None 21,817 48.1 0.59 <.0001  1,469 84.3 ref 
Single agent 2,877 6.3 0.36 <.0001  55 3.2 0.47 <.0001 
Multi-agent 20,653 45.5 0.30 <.0001  219 12.6 0.60 <.0001 
Surgeries          
0 23,260 51.3 0.51 <.0001  1,175 67.4 ref 
1 6,469 14.3 0.34 <.0001  207 11.9 0.82 0.0077 
>2 15,618 34.4 0.25 <.0001  361 20.7 0.48 <.0001 
Type of treatment          
None 10,335 22.8 0.55 <.0001  852 48.9 ref 
Surgery only 6,237 13.8 0.26 <.0001  372 21.3 0.54 <.0001 
Chemotherapy only 6,503 14.3 0.25 <.0001  141 8.1 0.42 <.0001 
Radiation only 2,889 6.4 0.39 <.0001  138 7.9 0.36 <.0001 
Chemotherapy and radiation 3,533 7.8 0.20 <.0001  44 2.5 0.25 <.0001 
Surgery and radiation 2,356 5.2 0.19 <.0001  107 6.1 0.22 <.0001 
Surgery and chemotherapy 7,009 15.5 0.16 <.0001  65 3.7 0.35 <.0001 
Surgery, radiation and 
chemotherapy 
6,485 14.3 0.14 <.0001  24 1.4 0.22 <.0001 
p-values reflect co parisons between the reference (ref) of each treatment type and the treatment group 
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Figure 5-1. Kaplan-Meier 5 year survival curve for cancer of unknown primary (CUP) 
and type of treatments received. 
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Figure 5-2. Kaplan-Meier 5 year survival curve for patients with metastatic tumours of 
known primary and type of treatments received. 
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Figure 5-3. Survival over 5 years for CUP and known primary patients stratified if 
treatment was received within six months of diagnosis, post six months after diagnosis or 
no treatment was received. 
 
  
0
10
20
30
40
50
60
70
80
90
100
0 to 6
months
6 to 12
months
12 to 18
months
18 to 24
months
24-30
months
30-36
months
36-60
months
Over 60
months
CUP, treatment post six
months after diagnosis
CUP, treatment within six
months of diagnosis
CUP, no treatment
All known primary
tumours, treatment post
six months after diagnosis
All known primary
tumours, treatment
within six months of
diagnosis
All known primary
tumours, no treatment
P
ro
p
o
rt
io
n
o
f 
p
at
ie
n
ts
 s
u
rv
iv
in
g 
w
it
h
in
 t
im
e 
w
in
d
o
w
Patient survival time window
 55 
Chapter 6 : Discussion 
 
In this study I have described two novel cohorts of Ontario metastatic cancer 
patients. Cross-validating data from the OCR and the SDS/DAD database I identified a 
cohort of CUP patients and metastatic cancer of known primary site patients. To my 
knowledge this work represents the first description of a CUP population of this size in 
Canada. This study revealed that CUP patients in Ontario represent a significant portion 
of all metastatic cancers, accounting for approximately 6.8% of the total metastatic 
population. I found that CUP patient survival varied by metastatic site and histology with 
nodal CUP patients having better survival than any other CUP metastatic site. Overall 
median survival of CUP patients was poor (1.9 months) compared to overall metastatic 
cancer of known primary patients (11.9 months). When I aggregated chemotherapy, 
radiation and surgery I discovered patients with a metastatic cancer of known primary 
were more likely to receive treatment (77.2%) than CUP patients (51.1%). 
While the description of this CUP population is novel in Canada, the patient 
characteristics and results largely confirm previous results in the literature. Increased 
survival in nodal CUP patients and patients with squamous cell histology has been 
described elsewhere (5, 8, 26) as well as decreased survival in respiratory/digestive CUP 
patients (30). These findings reinforce the factors describing unfavourable and favourable 
subgroups already known about CUP patients (35, 46). I did however, note Canadian 
specific traits in this population. In a large Swedish cohort, Hemminki et al. found 24% 
survival after one year (n=7,730), whereas I observed a one-year survival of 13.7% 
(n=349) for unspecified site CUP patients (10). This variation may be attributed to 
population differences or, more likely, to alternative diagnostic or therapeutic guidelines 
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that occurred over the different time frames. If this observed difference can be accounted 
for by diagnostic or post-diagnostic treatment, it will be important to try and implement 
this aspect into the Canadian setting. 
Comparing the survival of CUP patients to patients with metastatic cancer of 
known primary site suggests that knowledge of the originating malignancy may be 
integral to survival. The use of molecular tumour profiling in addition to routine 
diagnostic methods appears to directly address this idea. While this method does not 
physically locate the primary tumour, it does suggest a site based on the tumour gene 
expression profile. In an experimental trial, 247 of 289 patients had a tissue of origin 
predicted (37). Site-specific treatment was administered to 194 patients. The overall 
median survival was 12.5 months. This result is encouraging especially considering that I 
observed an OS of 1.9 months in CUP patients, however some caution is required in 
interpreting this finding. When breast and ovary were the predicted primary sites, median 
survival was over two years. Studies estimating the primary tumour site of CUP patients 
using death records place breast and ovary near one year median survival (25). The 
advent of this technology is likely to help CUP patients but may disproportionately 
benefit patients with favourable outcomes. 
Establishing a casual relationship between receiving treatment and survival 
outcomes in the CUP population is difficult. As mentioned previously those receiving 
treatment may be likely to have better survival outcomes. This is especially true for the 
favourable subgroup. These patients respond better to treatment while simultaneously 
having the benefit of site-specific treatment guidelines (5, 18). I did, however, observe 
increased survival in all CUP subgroups who received treatment. Furthermore, the 
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greatest reduction in HR was observed in patients receiving multiple treatments. These 
observations were mirrored in patients with a known primary tumour. The temporal 
relationship of treatment and survival was quite different in these populations. With a 
known primary, advanced survival coincided with early treatment, a trend not observed in 
the CUP population. Taken together these results may suggest CUP patients receiving 
treatment are fundamentally different than those who do not receive treatment. This 
difference may manifest as a responsiveness to treatment, but be rooted in a biologically 
distinct entity (47). Support for this argument can be seen in recent synthesis of 
unfavourable CUP patient treatment literature (16). Historically, therapeutic guidelines 
for CUP patients have recommended the use of platinum-based chemotherapy (5, 18, 35). 
Although targeted treatments may be available for some subgroups of patients, platinum-
based chemotherapy is often recommended to accompany such treatment (11). For the 
majority of CUP patients, a platinum-based doublet regimen is often prescribed (3). 
Phase II trials completed in the past 15 years have yielded inconclusive results regarding 
chemotherapy over best supportive care, and have not clarified the benefit of treatment 
regimens with platinum-based chemotherapy over non-platinum-based chemotherapy or 
single versus doublet or triplet chemotherapy regimens (16).  
 There are several areas of importance for future research in this field. The first is 
to understand the utility of molecular gene expression profiling in predicting primary 
tumours. If knowledge of the primary tumour site is clinically beneficial, the survival 
outcomes associated with this technique should reflect that idea. Secondly, clinical 
guidelines may need to be refined for the unfavourable population. CUP patients who are 
receiving empiric chemotherapy may not be experiencing survival benefit from their 
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treatment. This needs to be addressed. Ideally, these two research areas should coincide, 
the former providing a framework for treatment, and the later producing survival benefit 
for all CUP patients. 
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